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Abstract
Objectives To report the estimated trend in prevalence and
years lived with disability (YLDs) due to vision loss (VL) in
the EasternMediterranean region (EMR) from 1990 to 2015.
Methods The estimated trends in age-standardized preva-
lence and the YLDs rate due to VL in 22 EMR countries
were extracted from the Global Burden of Disease (GBD)
2015 study. The association of Socio-demographic Index
(SDI) with changes in prevalence and YLDs of VL was
evaluated using a multilevel mixed model.
Results The age-standardized prevalence of VL in the
EMR was 18.2% in 1990 and 15.5% in 2015. The total age-
standardized YLDs rate attributed to all-cause VL in EMR
was 536.9 per 100,000 population in 1990 and 482.3 per
100,000 population in 2015. For each 0.1 unit increase in
SDI, the age-standardized prevalence and YLDs rate of VL
showed a reduction of 1.5% (p\ 0.001) and 23.9 per
100,000 population (p\ 0.001), respectively.
Conclusions The burden of VL is high in the EMR;
however, it shows a descending trend over the past
25 years. EMR countries need to establish comprehensive
eye care programs in their health care systems.
Keywords Eastern Mediterranean region  Global burden
of disease  Vision impairment  Vision disorder
Introduction
Vision loss is an important public health issue worldwide.
About 90% of people with visual impairment live in
developing countries (Congdon et al. 2003; Tabbara 2001;
WHO 2004, 2013). According to the Global Burden of
Disease (GBD) 2015 study, 34.3 million people are blind
globally. In addition, 214 million and 24.3 million people
suffer from moderate and severe vision impairment (VI),
respectively. Vision loss was the third-ranked impairment
after anemia and hearing loss in the GBD 2015 study
(GBD 2015). Vision loss affects the quality of life of the
affected individuals and their families, increases the risk
of death by raising the risk of accidents, and increases the
financial burden (McCarty et al. 2001; Taylor et al.
1991, 2006). The World Health Organization (WHO)
Global Action Plan 2014–2019 emphasized the impor-
tance of collecting data on the burden and causes of VI.
Periodic studies were recommended to identify the burden
of vision loss and the avoidable causes of VI and blind-
ness to achieve a Global Action Plan target and plan
health policies (WHO 2013).
Uncorrected refractive errors (RE), cataract, glaucoma,
age-related macular degeneration (AMD), diabetic
retinopathy (DR), trachoma, and corneal opacities were the
main causes of global VI reported by WHO in 2010
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(Pascolini and Mariotti 2012). Uncorrected RE, cataract,
and glaucoma accounted for 43, 33, and 2% of VI,
respectively (Pascolini and Mariotti 2012). Hence, almost
80% of VI is preventable or treatable, and cost-effective
interventions can decrease the burden of VI (WHO 2013).
The Eastern Mediterranean region (EMR) has a popu-
lation of about 583 million and consists of 22 countries
(WHO 2017). These countries are not uniform in terms of
lifestyle, gross domestic product, and socioeconomic status
(Mandil et al. 2013; Mokdad et al. 2014). A previous study
reported a descending trend in age-standardized prevalence
of blindness (from 2.1 to 1.1%) and moderate and severe
VI (from 7.1 to 4.5%) in this region in 2010 (Khairallah
et al. 2014). Despite that, the EMR is one of four regions
with a greater than 4% prevalence of blindness among
older adults (C50 years), compared to B0.4% in high-in-
come regions (Stevens et al. 2013). The current study aims
to present trends in prevalence and years lived with dis-
ability (YLDs) rate for the main causes of vision loss in
EMR countries by sex and age from 1990 to 2015 using the
results of the GBD 2015 study. Considering the diversity of
the EMR countries in terms of socioeconomic status, the
relationship between the prevalence of vision loss and
Socio-demographic Index (SDI) was also evaluated.
Methods
We used data from the Global Burden of Disease 2015 study
(GBD 2015). The methodology of the GBD 2015 study for
estimating the prevalence of vision loss has been compre-
hensively described in a recent GBD publication (GBD
2015). In brief, the GBD group estimated the prevalence of
vision loss by defining VI and blindness, providing the input
model, and defining themodeling strategy. VIwas defined as
visual acuity (VA)\6/18 based on the Snellen chart, while
the blindness definition was VA\3/60 or visual field around
central fixation\10%. Uncorrected RE, cataract, glaucoma,
macular degeneration, and other causes including DR, tra-
choma, vitamin A deficiency, retinopathy of prematurity
(ROP), meningitis, encephalitis, and onchocerciasis were
used for modeling vision loss (GBD 2015).
The vision loss data were from population-based studies
that measured VA. Both peer-reviewed publications and
gray literature were used. Thosewhich reported the causes of
vision loss were used for estimating the VI and blindness
prevalence due to cataract, glaucoma,macular degeneration,
DR, and other causes (GBD 2015). Studies missing best-
corrected or presenting VA were excluded (GBD 2015).
A systematic literature review was performed for the
period of January 1, 2013–May 20, 2015, to add new
evidence to that compiled for GBD 2013. Additionally, the
data were extracted from WHO-sponsored Studies on
Global Ageing and Adult Health (SAGE) and the United
States National Health and Examination Surveys
(NHANES) as the nationally representative reviews that
measured VA. In addition to SAGE and NHANES, the
Surveys of Health, Ageing, and Retirement in Europe
(SHARE); the Multi-Country Survey Study on Health and
Responsiveness (MCSS); and the World Health Surveys
(WHS) studies were assessed to extract the data with self-
reported near VA (GBD 2015).
The prevalence of vision loss was modeled in three
stages. At first, the prevalence of moderate and severe VI,
blindness, and presbyopia was evaluated to calculate the
total presenting vision loss estimation. Secondly, the pro-
portion of presenting vision loss attributed to uncorrected
RE was estimated. Thirdly, the prevalence of vision loss
due to cataract, glaucoma, macular degeneration, DR,
ROP, trachoma, vitamin A deficiency, onchocerciasis,
meningitis, and other causes was assessed (GBD 2015).
The YLDs rate, a GBD metric, demonstrates years lived
in less than ideal health and is calculated by sequela as
prevalence multiplied by the disability weight for the
condition associated with that sequela (GBD 2015).
We extracted the estimated trends in prevalence and
YLDs rates for vision loss and four leading causes,
including refraction and accommodation disorders, catar-
act, glaucoma, and macular degeneration, in Afghanistan,
Bahrain, Djibouti, Egypt, Iran, Iraq, Jordan, Kuwait,
Lebanon, Libya, Morocco, Oman, Pakistan, Palestine,
Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia, the
United Arab Emirates, and Yemen from 1990 to 2015 from
the GBD 2015 study using an online interactive tool
(https://vizhub.healthdata.org/gbd-compare/) developed by
the Institute for Health Metrics and Evaluation. We also
determined the relationship between SDI and the reduction
in prevalence of vision loss and YLDs rate. The SDI was
developed for GBD 2015 to provide an interpretable syn-
thesis of overall development, as measured by lag-depen-
dent income per capita, average educational attainment in
the population over 15 years, and the total fertility rates. In
GBD 2015, SDI was computed by rescaling each compo-
nent to the scale of zero to one, and then taking the geo-
metric mean of these values for each location-year. Zero
indicates the lowest observed educational attainment,
lowest income per capita, and highest fertility rate from
1980 to 2015, and one indicates the highest observed
educational attainment, highest income per capita, and
lowest fertility rate during that time (GBD 2015).
Statistical methods
A multilevel linear model was used to assess the relation of
SDI values extracted from the GBD 2015 study for 22
countries in the EMR and the changes in prevalence and
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YLDs during the period 1990–2015. In this way, the
probable geographic correlation was also considered. All
statistics were presented with 95% uncertainty intervals
(95% UI). Statistical analysis was performed using lme4
package in R software (version 3.2.3) (Bates et al. 2015).
Results
The age-standardized prevalence of vision loss in the EMR
was 18.2% (95% UI 17.5–19%) in 1990 and 15.5% (95%
UI 14.8–16.2%) in 2015. The total age-standardized YLDs
rate attributed to vision loss in EMR was 536.9 per 100,000
population (95% UI 378.5–746) in 1990 and 482.3 per
100,000 population (95% UI 342.5–667.8) in 2015. Vision
loss was more prevalent in females than males in both 1990
and 2015 (p\ 0.001). There were similar findings in terms
of the estimated YLDs rate (p\ 0.001) (Fig. 1).
Table 1 shows decreased prevalence of vision loss and
the attributed YLDs rate in all 22 countries from 1990 to
2015. The highest decrease was observed in Oman
(prevalence -26.6, YLDs -16.2), while the lowest was
observed in Somalia (prevalence -1.6, YLDs -2.0).
A descending trend in the age-standardized prevalence
and YLDs rates for vision loss was noted among both sexes
from 1990 to 2015 (Fig. 2).
The age-standardized prevalence and YLDs rates of
vision loss in the EMR were higher than the global rate and
ranked third following the Southeast Asia and Africa
regions in 1990 and 2015. However, this region had the
highest reduction from 1990 to 2015 compared to all six
world regions (ESM_1).
Age-standardized prevalence and YLDs for causes
of vision loss
Refraction and accommodation disorders
The total age-standardized prevalence of refraction and
accommodation disorders in the EMR was 12.9% (95% UI
12.4–13.4%) in males and 17.8% (95% UI 17.1–18.6%) in
females in 1990. In 2015, these values were 10.8% (95% UI
10.3–11.2%) in males and 14.8% (95% UI 14.1–15.5%) in
females. The prevalence of this disorder in 1990 was highest
in Yemen and lowest in Lebanon. In 2015, Afghanistan had
the highest prevalence in terms of refraction and accom-
modation disorders (ESM_2). The age-standardized YLD
rate from refraction and accommodation disorders in the
EMR in 1990 amounted to 263.3 (95% UI 174.3–395.6) per
100,000 males and 337.9 (95%UI 221.9–518.7) per 100,000
females. In 2015, YLDs attributed to refraction and accom-
modation disorders in the EMR were 231.9 (95% UI
Fig. 1 Age-standardized prevalence and years lived with disability (YLDs) rate of vision loss in Eastern Mediterranean Region countries in
1990 and 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Countries, 1990–2015)
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154.4–344.7) per 100,000 males and 296.4 (95% UI
195.4–446.4) per 100,000 females. In 1990 and 2015, Egypt
had the highest age-standardized YLDs per 100,000 person,
and Lebanon had the lowest (ESM_2).
Cataract
The age-standardized prevalence of cataract in the EMR
was 1.5% (95% UI 1.3–1.6%) among males and 1.8%
(95% UI 1.6–2.0%) among females in 1990. The corre-
sponding values were 1.3% (95% UI 1.2–1.5%) in males
and 1.7% (95% UI 1.5–1.9%) in females in 2015 (ESM_3).
Cataract was most prevalent in Pakistan and least prevalent
in Libya in both 1990 and 2015.
Age-standardized YLDs attributed to cataract in the
EMR in 1990 were 97.9 (95% UI 70.3–132.7) per 100,000
population in males and 124.4 (95% UI 89.0–168.3) per
100,000 population in females. In 2015, the corresponding
values were 84.9 (95% UI 60.6–113.9) per 100,000 popu-
lation in males and 113.6 (95% UI 81.6–152.5) per 100,000
population in females (ESM_3). The highest rate of YLDs
per 100,000 population for cataract were observed in
Pakistan, and the lowest in Lebanon both in 1990 and 2015.
Glaucoma
In both 1990 and 2015, the highest age-standardized
prevalence of glaucoma was observed in Egypt, and the
Table 1 Age-standardized prevalence and years lived with disability rate per 100,000 population of vision loss in the Eastern Mediterranean
Region in 1990 and 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Countries, 1990–2015)
Location Prevalence (%) Percent
change
YLDs per 100,000 population Percent
change
1990 2015 1990 2015
Value 95% UI Value 95% UI Value 95% UI Value 95% UI
Lower Upper Lower Upper Lower Upper Lower Upper
Eastern
Mediterranean
Region
18.2 17.5 19 15.5 14.8 16.2 -15.1 536.9 378.5 746 482.3 342.5 667.8 -10.2
Afghanistan 23.8 21.9 25.8 20.7 19.1 22.4 -12.9 547.1 374.5 785.5 499 341.9 711.6 -8.8
Bahrain 15.5 14.3 16.9 13.2 12.2 14.4 -14.7 454.2 318.6 631.1 412.6 290.3 573.3 -9.2
Djibouti 15.6 13.9 17.5 14.1 12.5 15.7 -10.2 450.2 312.3 627.6 421.1 291.2 587.5 -6.5
Egypt 21.1 20.3 21.9 18.1 17.3 18.8 -14.5 642.7 456.6 893.5 586.8 418.2 807.3 -8.7
Iran 15.3 14.7 15.9 12.3 11.8 12.9 -19.5 468.3 331.2 647 413.2 295.4 563.9 -11.8
Iraq 18.9 17.4 20.6 16.1 14.8 17.6 -14.7 495.3 339.9 697 449.2 312.2 636.2 -9.3
Jordan 17.3 15.9 18.7 14.5 13.3 15.8 -16.1 473.9 329.1 667.6 429 299.7 596 -9.5
Kuwait 14.3 13.3 15.5 12.4 11.4 13.4 -13.7 436.2 305.6 604.9 398.8 280.1 552.1 -8.6
Lebanon 13.3 12.8 13.9 11.2 10.7 11.6 -16.1 319.4 220.9 457.4 290.6 202.7 408.5 -9
Libya 16.5 15.3 18 14.2 13.2 15.4 -14 439.8 310.3 613.3 400.3 283.8 556.6 -9
Morocco 22.7 21.9 23.5 19.2 18.5 19.9 -15.3 536.5 373.2 770.7 480.1 335.1 677.7 -10.5
Oman 19.3 17.9 20.8 14.1 13.2 15.3 -26.6 602.4 434.9 824.1 505 364.4 683.1 -16.2
Pakistan 16 15.3 16.8 14.1 13.4 14.8 -12.3 555.3 395.6 760.1 514.7 368.2 699 -7.3
Palestine 17.6 16.3 19 15.3 14.1 16.5 -13.3 392.7 267.6 574.1 360.4 249.3 517.5 -8.2
Qatar 15 14 16.1 12.6 11.8 13.5 -15.7 414.5 290.7 577.6 373.3 261.2 515.5 -9.9
Saudi Arabia 18.2 17.5 18.9 15 14.4 15.7 -17.4 451.8 310.1 644.2 402.3 275.8 569.2 -11
Somalia 18.9 16.8 21.2 18.6 16.6 20.8 -1.6 487.1 335.3 690.9 477.2 329.9 671 -2
Sudan 21.3 19.7 23.1 18.3 16.8 20 -14.1 524.5 360.6 744.2 476.1 327.7 669.7 -9.2
Syria 14.7 13.9 15.6 12.5 11.8 13.4 -14.7 458.8 321.9 637.8 416.7 294.7 574.1 -9.2
Tunisia 16.1 15.5 16.7 13.3 12.8 13.8 -17.6 402.3 280.7 571.8 364 254.4 506 -9.5
United Arab
Emirates
18.8 17.7 19.9 14.2 13.4 15.2 -24.4 478.5 329 678.5 408.6 284.8 572.7 -14.6
Yemen 24.8 23 26.8 19.2 17.8 20.7 -22.8 611.7 425.3 870.5 522.5 367.4 726.7 -14.6
UI uncertainty interval, YLDs years lived with disability
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lowest was reported in Afghanistan. Total age-standardized
prevalence of glaucoma in the EMR was 0.1% (95% UI
0.1–0.1%) in males and 0.2% (95% UI 0.1–0.2%) in
females in 1990, and 0.1% (95% UI 0.1–0.1%) in males
and 0.2% (95% UI 0.1–0.2%) in females in 2015 (ESM_4).
In 1990, glaucoma accounted for 10.7 age-standardized
YLDs (95% UI 7.3–14.8) per 100,000 for males and 15.4
age-standardized YLDs (95% UI 10.5–21.1) per 100,000
for females in the EMR. The rate of age-standardized
YLDs for glaucoma in 2015 was 11.5 (95% UI 7.9–16.1)
per 100,000 for males and 16.7 (95% UI 11.6–23.1) per
100,000 females in this region (ESM_4). YLDs attributed
to glaucoma were highest in Oman and lowest in Pakistan
in 1990, and highest in Egypt and lowest in Lebanon in
2015.
Macular degeneration
The age-standardized prevalence of macular degeneration
in the EMR was 0.1% (95% UI 0.1–0.1%) among males
and 0.1% (95% UI 0.1–0.1%) among females in 1990. In
2015, the corresponding values were 0.1% (0.1–0.1%) in
males and 0.1% (95% UI 0.1–0.1%) in females in 2015
(ESM_5). Among the 22 countries, Kuwait had the highest
and Afghanistan had the lowest prevalence of macular
degeneration in 1990. However, macular degeneration was
most prevalent in Oman and least prevalent in Somalia in
2015.
The age-standardized YLDs rate associated with mac-
ular degeneration in the EMR was 6.0 (95% UI 4.1–8.3)
per 100,000 for males and 6.5 (95% UI 4.5–9.1) per
100,000 for females in 1990, increasing to 8.1 (95% UI
5.6–11.2) per 100,000 males and 9.0 (95% UI 6.2–12.6) per
100,000 females in 2015 (ESM_5). In both 1990 and 2015,
Oman had the highest and Somalia had the lowest YLDs
attributed to macular degeneration.
Other causes of vision loss
Saudi Arabia had the highest prevalence of other causes of
vision loss, and Somalia had the lowest. In 1990, the age-
standardized prevalence of other causes of vision loss was
0.4% (95% UI 0.4–0.4%) in males and 0.5% (95% UI
0.4–0.5%) in females. Corresponding values were 0.5%
(95% UI 0.4–0.5%) in males and 0.5% (95% UI 0.4–0.5%)
in females in 2015 (ESM_6).
Oman had the largest burden of age-standardized YLDs
rate for other causes of vision loss and Lebanon had the
smallest in both 1990 and 2015. Age-standardized YLDs
were 34.9 (95% UI 24.7–47.6) per 100,000 males and 35.5
(95% UI 25.0–47.8) per 100,000 females in 1990, and 37.7
(95% UI 26.8–51.0) per 100,000 males and 38.6 (95% UI
27.2–51.8) per 100,000 females in 2015 (ESM_6).
Age-specific prevalence of the leading causes
of vision loss
The main causes of vision loss, including cataract, glau-
coma, macular degeneration, and the category ‘‘other
causes of vision loss’’ were most prevalent in the popula-
tion aged 80 and older in both 1990 and 2015. The highest
prevalence of refraction and accommodation disorders was
noted among people aged 70–74 years in 1990 and 2015
(Fig. 3).
Fig. 2 Trends in age-standardized prevalence and years lived with disability (YLDs) rate of vision loss by gender in the Eastern Mediterranean
Region from 1990 to 2015 (Global Burden of Disease Study 2015, Eastern Mediterranean Region, 1990–2015)
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Leading causes of age-specific YLDs rate for vision
loss
Figure 3 shows the highest YLDs rates for cataract, glau-
coma, macular degeneration, and other causes of vision
loss in the population aged 80 or older in 1990 and 2015.
The highest rate of YLDs for refraction and accommoda-
tion disorders was demonstrated in the age group
70–74 years in 1990 and 2015 (Fig. 3).
Association of SDI and changes in age-standardized
prevalence and YLDs rate of vision loss
For each 0.1 unit increase in SDI, the age-standardized
prevalence of vision loss due to all causes showed a 1.5%
reduction using a multilevel linear model (p\ 0.001).
Corresponding values for each cause are presented in
Table 2 and Fig. 4.
For each 0.1 unit increase in SDI, a 23.9 per 100,000
population reduction in the age-standardized YLDs rate for
vision loss due to all causes was noted using a multilevel
linear model (p\ 0.001). Cause-specific YLDs are shown
in Table 2 and Fig. 4.
Ratio of observed-to-expected prevalence and YLDs
of vision loss based on SDI
ESM_7 shows that United Arab Emirates had the highest
and Syria had the lowest observed-to-expected ratio (O/E)
for prevalence of vision loss due to all causes based on
SDI. The highest O/E YLDs ratio was noted in the Egypt,
whereas Lebanon had the lowest ratio (ESM_8).
Discussion
This is the first report on the burden of vision loss in the
EMR countries during 1990–2015 (GBD 2015). Our find-
ings indicated a decline in the age-standardized and age-
specific prevalence and YLDs rate of vision loss from 1990
to 2015. However, vision loss still presents a burden in the
region and needs to be addressed in health policies.
Our findings on trends were compatible with the results
of the Khairallah et al. study, which showed a descending
trend in age-standardized prevalence of blindness and
moderate and severe VI in the Middle East and North
Africa from 1990 to 2010 (Khairallah et al. 2014). Despite
a declining trend in age-standardized prevalence and YLDs
rate of vision loss over the past 25 years in the EMR, a
wide disparity among the 22 countries in this region was
demonstrated in terms of vision loss prevalence and YLDs
rate. This can be explained by the difference in socio-de-
mographic conditions and capacities of health systems in
these countries (Mandil et al. 2013; Mokdad et al. 2014).
On the other hand, in recent years, a number of EMR
countries have been involved in conflicts and wars,
resulting in limited health resources (Mokdad et al. 2016).
Unfavorable and unstable socioeconomic conditions can
also lead to a lack of strategic plans and operational pro-
grams for the prevention and treatment of VI and blindness.
The EMR had a higher age-standardized prevalence and
YLDs rate of vision loss compared to the global rate and
ranked third following the Southeast Asia and Africa
regions in 2015. Stevens et al. reported a greater than 4%
prevalence of blindness in older adults in Western sub-
Saharan Africa, Eastern sub-Saharan Africa, the EMR, and
Fig. 3 Age-specific prevalence (a, b) and years lived with disability (YLDs) rate (c, d) for causes of vision loss in Eastern Mediterranean Region
at two time points (1990 and 2015) (Global Burden of Disease Study 2015, Eastern Mediterranean Region, 1990, 2015)
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South Asia in 2010 (Stevens et al. 2013). However, the
highest reduction was observed in this region from 1990 to
2015 compared to all six world regions.
With regard to gender disparity, females were more
affected by vision loss in the EMR, consistent with the
global findings of the GBD 2015 study and other studies
reporting on the EMR (Abou-Gareeb et al. 2001; GBD
2015; Hashemi et al. 2012; Jadoon et al. 2006; Khairallah
et al. 2014; Rajavi et al. 2016; Stevens et al. 2013; WHO
2007). The gender disparity might be due to allocation of
less family financial resources, resulting in limited access
to eye care services for females (Hashemi et al. 2012;
Table 2 Association of Socio-
demographic Index and changes
in age-standardized prevalence
and years lived with disability
rate of vision loss from 1990 to
2015 in the Eastern
Mediterranean Region (Global
Burden of Disease Study 2015,
Eastern Mediterranean Region,
1990–2015)
Metric Cause of vision loss Estimate 95% UI p value
Lower Upper
Prevalence All causes -1.51 -1.59 -1.43 \0.001
Refraction and accommodation disorders -1.46 -1.53 -1.39 \0.001
Cataract -0.04 -0.05 -0.03 \0.001
Glaucoma 0.00 0.00 0.01 \0.001
Macular degeneration 0.01 0.01 0.01 \0.001
Other vision loss 0.02 0.01 0.02 \0.001
YLDs All causes -23.94 -26.68 -21.20 \0.001
Refraction and accommodation disorders -17.89 -19.11 -16.67 \0.001
Cataract -4.41 -5.42 -3.40 \0.001
Glaucoma 0.25 0.07 0.42 0.007
Macular degeneration 0.90 0.81 0.98 \0.001
Other vision loss 0.88 0.50 1.27 \0.001
SDI socio-demographic index, UI uncertainty interval, YLDs years lived with disability
Fig. 4 Association of Socio-demographic Index (SDI) and changes
in age-standardized prevalence and years lived with disability (YLDs)
rate of all-cause vision loss (a), refraction and accommodation
disorders (b), cataract (c), glaucoma (d), macular degeneration (e),
and other causes of vision loss (f) (Global Burden of Disease Study
2015, Eastern Mediterranean Region, 2015)
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Stevens et al. 2013). This inequality may be attributed to
cultural backgrounds which could be overcome by pro-
moting awareness and education in affected societies.
Our results follow previous global and regional studies
that reported refraction and accommodation disorders,
cataract, glaucoma, and macular degeneration as the main
causes of vision loss (GBD 2015; Khairallah et al. 2014;
Katibeh et al. 2017a, b; Ko¨berlein et al. 2013; Naidoo et al.
2014; Keeffe et al. 2014). Among these, refraction and
accommodation disorders remained the most prevalent in
the EMR from 1990 to 2015. A similar global-scale finding
was reported in the GBD 2015 study and WHO global data
2010 (GBD 2015; Pascolini and Mariotti 2012; Bourne
et al. 2013; Resnikoff et al. 2008; Naidoo et al. 2016).
However, a decreasing trend in age-standardized preva-
lence and YLDs rate due to refraction and accommodation
disorders was observed in this region. There was a 1.46%
reduction in age-standardized prevalence and 17.89 per
100,000 population reduction in YLDs from refraction and
accommodation disorders per 0.1 unit improvement in SDI
score in the current study. Refraction and accommodation
disorders had a considerable impact on the socioeconomic
condition of the affected persons and their families via
limiting educational and employment opportunities,
resulting in productivity loss (Naidoo and Jaggernath 2012;
Smith et al. 2009). A large amount of vision loss can be
potentially prevented and cured through developing and
implementing national screening programs and cost-effec-
tive interventions (WHO 2013).
Cataract was the second-ranked cause of vision loss in
the EMR in both 1990 and 2015, with female predomi-
nance that was compatible with global findings from the
GBD 2015 study (GBD 2015). The global WHO report
also indicated that cataracts accounted for 33% of VI and
51% of blindness in 2010 (Pascolini and Mariotti 2012).
Considering the geographic location of EMR countries,
ultraviolet radiation may play a role in the high prevalence
of cataract in this region (McCarty and Taylor 2002).
Cataract can be treated simply with a timely and cost-
effective intervention which would result in favorable
visual outcomes; therefore it is categorized as a pre-
ventable cause of blindness (Pascolini and Mariotti 2012;
WHO 2013). We found a significant correlation between
the improvement of SDI score (by 0.1 unit) and the 0.04%
reduction in age-standardized prevalence and 4.41 per
100,000 population reduction in the rate of YLDs from
vision loss due to cataract in the EMR, which was in line
with the Mundy et al. study. They reviewed the literature to
report the association of cataract care with socioeconomic
parameters in both developed and developing countries.
These parameters can lead to limited access to primary eye
care services. Promotion of education can improve the
acceptability of these resources in low socioeconomic areas
(Mundy et al. 2016).
Glaucomawas the third-leading cause of vision loss in the
EMR. A slightly ascending trend of age-standardized
prevalence and the rate of YLDs from glaucoma were
observed over our study period. This finding follows the
global results in the GBD 2015 study (GBD 2015). A meta-
analysis by Bourne et al. showed an increased percentage of
blindness due to glaucoma from 1990 to 2010 globally, with
no significant difference between regions (Bourne et al.
2016). We also found that the slightly increasing age-stan-
dardized YLDs rate of glaucoma (0.25 per 100,000 person)
was associated with the improved SDI score (by 0.1 unit).
Given the increasing trend of vision loss due to glaucoma, a
number of issues should be considered for public health
planning. First, glaucoma and macular degeneration are
responsible for the majority of irreversible blindness in the
world. One out of 15 cases of blindness and one out of 45
cases of VI were due to glaucoma by 2010 (Bourne et al.
2016). Early diagnosis and proper medical and surgical
management can prevent blindness due to glaucoma. Sec-
ondly, the Bourne et al. study also revealed that regions with
younger populations had lower percentages of blindness due
to glaucoma compared to high-income regions with older
populations (Bourne et al. 2016). Tham et al. demonstrated
the highest prevalence of glaucoma in Africa (primary open-
angle glaucoma 4.20%) and Asia (primary angle-closure
glaucoma 1.20%) in 2013 (Tham et al. 2014). Therefore,
considering increasing life expectancy, the prevalence of VI
due to glaucoma is expected to increase in the EMR in the
future. Clinical and targeted screening would be appropriate
approaches for preventing vision loss due to glaucoma
(Mohammadi et al. 2014).
Macular degeneration was the fourth-leading cause of
vision loss in terms of prevalence and YLDs rate in the
EMR. An increasing trend was observed in age-standard-
ized prevalence and rate of YLDs due to macular degen-
eration in both sexes. Our finding is consistent with the
global results from GBD 2015 and the meta-analysis from
1990 to 2010 (GBD 2015; Jonas et al. 2014). This meta-
analysis demonstrated a lower prevalence of macular
degeneration in regions with younger populations in com-
parison with high-income regions (Jonas et al. 2014). Our
study also showed that the increase in age-standardized
prevalence (0.01%) and YLDs rate (0.9 per 100,000 per-
son) of macular degeneration from 1990 to 2015 was
associated with the improvement of SDI score (by 0.1
unit). With regard to the aging population and availability
of effective interventions, especially intravitreal anti-vas-
cular endothelial growth factor drugs, macular degenera-
tion may be recognized as an important public eye health
issue for future planning (Jonas et al. 2014).
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Our study has a few limitations. Vision loss due to
diabetes mellitus is considered part of the diabetes burden
and is not included in our study (Moradi-Lakeh et al.
2017). Considering the high prevalence of diabetes in
EMR, the burden of VI may be higher than what is esti-
mated in this study (Katibeh et al. 2017a, b; Khandekar
2012; WHO 2016). Some of the countries in the region do
not have appropriate data on the epidemiology of low
vision or have used nonstandard methods for measuring
and reporting vision loss. We used the GBD general
methodology to produce more accurate estimates using
different study-level or country-level covariates.
Conclusions
The current study provides an up-to-date estimation based
on the GBD 2015 study, demonstrating a high prevalence
and high rate of YLDs due to vision loss with a decreasing
trend in the EMR. Our findings call for developing and
implementing programs to manage refraction and accom-
modation disorders and cataract due to their large burden.
There is a need for balance between prevention and treat-
ment programs to reduce the burden of vision loss in the
region. This can be achieved by developing and imple-
menting a national operational program and involving all
related stakeholders. Education campaigns might be useful
to promote public awareness.
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